JP2004514644A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004514644A5 JP2004514644A5 JP2001564799A JP2001564799A JP2004514644A5 JP 2004514644 A5 JP2004514644 A5 JP 2004514644A5 JP 2001564799 A JP2001564799 A JP 2001564799A JP 2001564799 A JP2001564799 A JP 2001564799A JP 2004514644 A5 JP2004514644 A5 JP 2004514644A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- groups
- group
- backbone
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 38
- 239000000816 peptidomimetic Substances 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 125000002091 cationic group Chemical group 0.000 description 11
- 239000000126 substance Substances 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- -1 ketomethylene Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 108010043958 Peptoids Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 1
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical compound N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0005703.4A GB0005703D0 (en) | 2000-03-09 | 2000-03-09 | Compounds |
| PCT/GB2001/001035 WO2001066147A2 (en) | 2000-03-09 | 2001-03-09 | Antimicrobial compounds and formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012158714A Division JP5554810B2 (ja) | 2000-03-09 | 2012-07-17 | 抗菌化合物および処方物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004514644A JP2004514644A (ja) | 2004-05-20 |
| JP2004514644A5 true JP2004514644A5 (https=) | 2012-09-06 |
Family
ID=9887297
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001564799A Pending JP2004514644A (ja) | 2000-03-09 | 2001-03-09 | 抗菌化合物および処方物 |
| JP2012158714A Expired - Fee Related JP5554810B2 (ja) | 2000-03-09 | 2012-07-17 | 抗菌化合物および処方物 |
| JP2014081982A Expired - Fee Related JP5747100B2 (ja) | 2000-03-09 | 2014-04-11 | 抗菌化合物および処方物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012158714A Expired - Fee Related JP5554810B2 (ja) | 2000-03-09 | 2012-07-17 | 抗菌化合物および処方物 |
| JP2014081982A Expired - Fee Related JP5747100B2 (ja) | 2000-03-09 | 2014-04-11 | 抗菌化合物および処方物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7232803B2 (https=) |
| EP (2) | EP1263471B1 (https=) |
| JP (3) | JP2004514644A (https=) |
| AT (1) | ATE528017T1 (https=) |
| AU (2) | AU2001237616B2 (https=) |
| CA (1) | CA2400410C (https=) |
| DK (1) | DK1263471T3 (https=) |
| GB (1) | GB0005703D0 (https=) |
| NO (1) | NO334230B1 (https=) |
| WO (1) | WO2001066147A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8283315B2 (en) | 1998-08-28 | 2012-10-09 | Lytix Biopharma As | Inhibition of tumour growth |
| GB0005703D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
| AU2001270098A1 (en) * | 2000-06-22 | 2002-01-02 | San Diego State University Foundation | Recombination modulators and methods for their production and use |
| NO20031818D0 (no) * | 2003-04-23 | 2003-04-23 | Uni I Tromsoe | Fremgangsmåte av bioaktiv peptid forberedelse |
| JP4879020B2 (ja) * | 2003-05-01 | 2012-02-15 | コーネル リサーチ ファウンデイション インコーポレイテッド | 細胞に分子を送達する方法及び担体複合体 |
| WO2005074968A2 (en) * | 2004-02-10 | 2005-08-18 | Universiteit Maastricht | Medical use of basic peptides |
| WO2007127457A2 (en) * | 2006-04-28 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof |
| US7960339B2 (en) * | 2006-07-10 | 2011-06-14 | Österreichische Akademie der Wissenschaften | Antimicrobial peptides |
| GB0724951D0 (en) | 2007-12-20 | 2008-01-30 | Lytix Biopharma As | Compounds |
| GB0724953D0 (en) | 2007-12-20 | 2008-01-30 | Lytix Biopharma As | Methods of peptide modification |
| US9139355B2 (en) * | 2008-04-18 | 2015-09-22 | Medline Industries, Inc. | Glove packaging having antimicrobial barrier |
| US9409946B2 (en) | 2008-06-17 | 2016-08-09 | Peptisyntha | Peptide manufacturing process |
| GB0818074D0 (en) * | 2008-10-02 | 2008-11-05 | Lytix Biopharma As | Treatment of biofilms |
| GB0821616D0 (en) | 2008-11-26 | 2008-12-31 | Lytix Biopharma As | Compounds |
| US9724381B2 (en) | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
| WO2011009903A2 (de) * | 2009-07-21 | 2011-01-27 | Udo Bogner | Endoperoxidhaltiges materialsystem mit anpassung des zerfalls und anwendungen |
| US9550811B2 (en) | 2010-12-02 | 2017-01-24 | Bionor Immuno As | Peptide scaffold design |
| US9493514B2 (en) | 2011-01-06 | 2016-11-15 | Bionor Immuno As | Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes |
| WO2012154959A1 (en) * | 2011-05-11 | 2012-11-15 | Elixir Institute Of Regenerative Medicine | Peptide tyrosinase inhibitors and uses thereof |
| US20150018311A1 (en) * | 2012-01-09 | 2015-01-15 | University of Tromsø | Therapeutic boron-containing compounds |
| CN104363756B (zh) * | 2012-04-18 | 2017-10-31 | 农村振兴厅 | 含有二肽衍生物作为活性成分的农业植物‑保护剂 |
| JP6310909B2 (ja) | 2012-06-06 | 2018-04-11 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド |
| TWI577697B (zh) * | 2013-11-28 | 2017-04-11 | 國立清華大學 | 耐高鹽及抗蛋白之抗菌胜肽及其製造方法 |
| EP3071591B1 (en) * | 2014-01-22 | 2021-05-05 | Agency For Science, Technology And Research | Antimicrobial peptidomimetics |
| EP3497965B1 (en) | 2016-08-11 | 2022-04-13 | Kyocera Corporation | Ran-assisted rate adaptation |
| WO2018160791A1 (en) | 2017-03-03 | 2018-09-07 | Massachusetts Institute Of Technology | Antimicrobial constructs and uses thereof |
| CN110938112A (zh) * | 2019-12-10 | 2020-03-31 | 倪京满 | 脂肪酸修饰的超短序列抗菌肽类似物及其应用 |
| CN110950932B (zh) * | 2020-01-09 | 2023-04-18 | 福州大学 | 一种修饰肽的制备及其应用 |
| US20230109142A1 (en) | 2020-02-14 | 2023-04-06 | Immunor As | Corona virus vaccine |
| CN113248572B (zh) * | 2021-04-30 | 2023-04-11 | 重庆理工大学 | 一种抗多重耐药菌环肽及其应用 |
| CN120476131A (zh) * | 2023-01-05 | 2025-08-12 | 埃米考特公司 | 涉及位阻三叔丁基色氨酸（Tbt）残基的肽合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668254A (en) * | 1990-05-11 | 1997-09-16 | Romano Deghenghi | D-2-alkyl-tryptophan and peptides containing same |
| JP3009718B2 (ja) * | 1990-10-01 | 2000-02-14 | 日本合成化学工業株式会社 | 新規ペプチド、その製造法及び用途 |
| JP2771068B2 (ja) * | 1991-03-13 | 1998-07-02 | 森永乳業株式会社 | 抗菌性ペプチドおよび抗菌剤 |
| NZ241936A (en) * | 1991-03-13 | 1994-03-25 | Morinaga Milk Industry Co Ltd | Antimicrobial peptide and its use in an antimicrobial composition |
| DK0510912T3 (da) * | 1991-04-24 | 1998-02-09 | Morinaga Milk Industry Co Ltd | Antimikrobielt peptid og antimikrobielt middel |
| JP3173857B2 (ja) * | 1991-04-24 | 2001-06-04 | 森永乳業株式会社 | 抗菌性ペプチドおよび抗菌剤 |
| JP3173858B2 (ja) * | 1991-04-24 | 2001-06-04 | 森永乳業株式会社 | 抗菌性ペプチドおよび抗菌剤 |
| US5547939A (en) * | 1991-06-14 | 1996-08-20 | The Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
| US5885782A (en) * | 1994-09-13 | 1999-03-23 | Nce Pharmaceuticals, Inc. | Synthetic antibiotics |
| WO1997000889A1 (en) * | 1995-06-21 | 1997-01-09 | Asahi Kasei Kogyo Kabushiki Kaisha | Peptides binding to low-density lipoproteins |
| IL117223A0 (en) | 1996-02-22 | 1996-06-18 | Yeda Res & Dev | Antipathogenic polypeptides and compositions comprising them |
| IL118003A0 (en) * | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
| US5948889A (en) | 1996-05-21 | 1999-09-07 | Case Western Reserve University | Compositions and methods for screening antimicrobials |
| DE19818802A1 (de) * | 1998-04-27 | 1999-10-28 | Dresden Arzneimittel | Stabile Mitoxantron-Lösungen |
| PL344049A1 (en) * | 1998-05-18 | 2001-09-24 | Upjohn Co | Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives |
| GB9818938D0 (en) * | 1998-08-28 | 1998-10-21 | Alpharma As | Bioactive peptides |
| GB0005702D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Method |
| GB0005703D0 (en) * | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
| US20030059827A1 (en) * | 2001-03-13 | 2003-03-27 | Cayetano Gonzalez | Engineered protein binding domains and methods and systems for their design and use |
| US7291698B2 (en) * | 2001-09-04 | 2007-11-06 | Stephen Eliot Zweig | Synthetic substrate for high specificity enzymatic assays |
-
2000
- 2000-03-09 GB GBGB0005703.4A patent/GB0005703D0/en not_active Ceased
-
2001
- 2001-03-09 EP EP01910034A patent/EP1263471B1/en not_active Expired - Lifetime
- 2001-03-09 AT AT01910034T patent/ATE528017T1/de not_active IP Right Cessation
- 2001-03-09 EP EP10011411A patent/EP2338522A1/en not_active Withdrawn
- 2001-03-09 AU AU2001237616A patent/AU2001237616B2/en not_active Ceased
- 2001-03-09 US US10/221,040 patent/US7232803B2/en not_active Expired - Fee Related
- 2001-03-09 WO PCT/GB2001/001035 patent/WO2001066147A2/en not_active Ceased
- 2001-03-09 DK DK01910034.6T patent/DK1263471T3/da active
- 2001-03-09 CA CA2400410A patent/CA2400410C/en not_active Expired - Fee Related
- 2001-03-09 AU AU3761601A patent/AU3761601A/xx active Pending
- 2001-03-09 JP JP2001564799A patent/JP2004514644A/ja active Pending
-
2002
- 2002-09-04 NO NO20024218A patent/NO334230B1/no not_active IP Right Cessation
-
2007
- 2007-04-20 US US11/738,098 patent/US8048852B2/en not_active Expired - Fee Related
-
2011
- 2011-09-22 US US13/239,662 patent/US9115169B2/en not_active Expired - Fee Related
-
2012
- 2012-07-17 JP JP2012158714A patent/JP5554810B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-11 JP JP2014081982A patent/JP5747100B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004514644A5 (https=) | ||
| JP5747100B2 (ja) | 抗菌化合物および処方物 | |
| AU2016208308B2 (en) | Peptides and their use | |
| JP5810090B2 (ja) | 治療用ペプチド | |
| AU747668B2 (en) | Inhibition of major groove DNA binding proteins by modified polyamides | |
| CN101970459B (zh) | 抗微生物化合物 | |
| AU2001237616A1 (en) | Antimicrobial compounds and formulations | |
| US9518093B2 (en) | Topical formulation of arginine-rich cyclic antimicrobial peptides | |
| US20120238508A1 (en) | Methods for Promoting Wound Healing and/or Reducing Scar Formation | |
| US20190031730A1 (en) | Formulation of mk2 inhibitor peptides | |
| US20040110678A1 (en) | Novel drug delivery system | |
| JP4817335B2 (ja) | 新規抗菌性ペプチド | |
| DE60025332T2 (de) | Synthetisches peptid zur störung intrazellulärer signale | |
| JP4642469B2 (ja) | カルシニューリンの恒常的活性化阻害剤 | |
| WO2009154264A1 (ja) | ペプチド | |
| WO2014075137A1 (en) | Peptides incorporating amino-substituted lactams for treatment of retinopathy | |
| TW387896B (en) | Novel dipeptide and tripeptide mimic compounds for treating Parkinson's disease | |
| AU2007200957C1 (en) | Methods for promoting wound healing and/or reducing scar formation | |
| ITRM960032A1 (it) | Peptidi derivati da cd4, analoghi e usi di essi in diagnosi e terapia |